A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

Also called NCT02025907

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 218 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02025907
  • EudraCT 2013-004819-40
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, France, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02025907. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-09-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin, 100 mg
Intervention (Drug)
Canagliflozin, 300 mg
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct02025907
Content hash
d4fb2f609530e88c234411e75fb647d54edb6d1121d445082ea5c9ed1fff3b84